###begin article-title 0
IFN-gamma Mediates the Rejection of Haematopoietic Stem Cells in IFN-gammaR1-Deficient Hosts
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 483 488 <span type="species:ncbi:10090">mouse</span>
Interferon-gamma receptor 1 (IFN-gammaR1) deficiency is a life-threatening inherited disorder, conferring predisposition to mycobacterial diseases. Haematopoietic stem cell transplantation (HSCT) is the only curative treatment available, but is hampered by a very high rate of graft rejection, even with intra-familial HLA-identical transplants. This high rejection rate is not seen in any other congenital disorders and remains unexplained. We studied the underlying mechanism in a mouse model of HSCT for IFN-gammaR1 deficiency.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 170 173 170 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 201 204 201 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 235 254 235 254 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Mycobacterium bovis</named-content>
###xml 354 360 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 360 363 356 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 496 502 484 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 502 505 490 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 596 602 584 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 602 605 590 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 608 612 596 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng</italic>
###xml 612 615 600 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 731 737 715 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 737 740 721 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 235 254 <span type="species:ncbi:1765">Mycobacterium bovis</span>
###xml 255 279 <span type="species:ncbi:33892">bacillus Calmette-Guerin</span>
###xml 281 284 <span type="species:ncbi:33892">BCG</span>
###xml 337 343 <span type="species:ncbi:9606">humans</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 630 634 <span type="species:ncbi:10090">mice</span>
###xml 647 650 <span type="species:ncbi:33892">BCG</span>
###xml 741 745 <span type="species:ncbi:10090">mice</span>
We demonstrated that HSCT with cells from a syngenic C57BL/6 Ifngr1+/+ donor engrafted well and restored anti-mycobacterial immunity in naive, non-infected C57BL/6 Ifngr1-/- recipients. However, Ifngr1-/- mice previously infected with Mycobacterium bovis bacillus Calmette-Guerin (BCG) rejected HSCT. Like infected IFN-gammaR1-deficient humans, infected Ifngr1-/- mice displayed very high serum IFN-gamma levels before HSCT. The administration of a recombinant IFN-gamma-expressing AAV vector to Ifngr1-/- naive recipients also resulted in HSCT graft rejection. Transplantation was successful in Ifngr1-/- x Ifng-/- double-mutant mice, even after BCG infection. Finally, efficient antibody-mediated IFN-gamma depletion in infected Ifngr1-/- mice in vivo allowed subsequent engraftment.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 348 353 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
High serum IFN-gamma concentration is both necessary and sufficient for graft rejection in IFN-gammaR1-deficient mice, inhibiting the development of heterologous, IFN-gammaR1-expressing, haematopoietic cell lineages. These results confirm that IFN-gamma is an anti-haematopoietic cytokine in vivo. They also pave the way for HSCT management in IFN-gammaR1-deficient patients through IFN-gamma depletion from the blood. They further raise the possibility that depleting IFN-gamma may improve engraftment in other settings, such as HSCT from a haplo-identical or unrelated donor.
###end p 6
###begin p 7
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Claire Soudais and colleagues investigated the mechanism of rejection of hematopoietic stem cell transplants in patients with interferon-gamma receptor 1 (IFN-gammaR1) deficiency and show that IFN-gamma is an anti-hematopoietic cytokine in vivo.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 426 452 422 448 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Mycobacterium tuberculosis</named-content>
###xml 457 466 453 462 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">M. leprae</named-content>
###xml 1381 1389 1357 1365 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">M. bovis</named-content>
###xml 272 278 <span type="species:ncbi:9606">People</span>
###xml 426 452 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
###xml 457 466 <span type="species:ncbi:1769">M. leprae</span>
###xml 547 552 <span type="species:ncbi:9606">human</span>
###xml 576 582 <span type="species:ncbi:9606">people</span>
###xml 1265 1273 <span type="species:ncbi:9606">patients</span>
###xml 1381 1393 <span type="species:ncbi:33892">M. bovis BCG</span>
Normally, the body's immune system efficiently recognizes and kills bacteria and viruses, but in some rare inherited disorders ("primary immunodeficiencies") part of the immune system works poorly or is missing. This leaves affected individuals susceptible to infections. People with one of these disorders-interferon-gamma receptor 1 (IFN- gammaR1) deficiency-are very susceptible to infections with mycobacteria. Except for Mycobacterium tuberculosis and M. leprae (which cause tuberculosis and leprosy, respectively), mycobacteria rarely cause human disease. However, most people with IFN-gammaR1 deficiency die during childhood from multiple, widespread mycobacterial infections, because IFN-gammaR1 deficiency disables a specific part of their immune system. When most bacteria enter the body, immune system cells called macrophages engulf and kill them, but mycobacteria actually multiply inside macrophages. This infection stimulates lymphocytes and other immune system cells to release IFN-gamma, which binds to IFN-gammaR1 on uninfected macrophages, activates them, and recruits them to the infection site. Here, they form a "granuloma," a mass of macrophages and activated lymphocytes that "walls off" the infection. Granuloma formation does not occur in patients with IFN-gammaR1 deficiency, so mycobacteria (including the usually benign tuberculosis vaccination strain M. bovis BCG) spread throughout the body with disastrous consequences.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 227 233 223 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFNGR1</italic>
###xml 760 766 748 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 767 768 755 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 766 769 754 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 769 770 757 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8212;</italic>
###xml 827 833 815 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 834 835 822 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 833 836 821 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 253 260 <span type="species:ncbi:9606">patient</span>
###xml 455 462 <span type="species:ncbi:9606">patient</span>
###xml 732 737 <span type="species:ncbi:10090">mouse</span>
###xml 818 822 <span type="species:ncbi:10090">mice</span>
###xml 858 863 <span type="species:ncbi:9606">human</span>
###xml 864 872 <span type="species:ncbi:9606">patients</span>
###xml 880 884 <span type="species:ncbi:10090">mice</span>
The only effective treatment for patients with IFN-gammaR1 deficiency is hematopoietic stem cell transplantation (HSCT). HSCs are the source of all the immune system cells, so transplantation of HSCs from a donor with a normal IFNGR1 gene can provide a patient who has IFN-gammaR1 deficiency with a new immune system that can combat mycobacterial infections. Unfortunately, in this particular immune deficiency, the new HSCs cannot engraft, even when the patient's own immune system is disabled before HSCT by intensive chemotherapy, and when the donor cells come from a close relative and are a good immunological match. In this study, the researchers have investigated why rejection is so common in IFN-gammaR1 deficiency using a mouse strain called C57BL/6 Ifngr1-/--C57BL/6 denotes the genetic background of these mice and Ifngr1-/- indicates that, like human patients, these mice make no IFN-gammaR1.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 7 8 7 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 6 9 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 55 63 55 63 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">M. bovis</named-content>
###xml 192 195 188 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 186 195 182 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>+/+</sup></italic>
###xml 228 236 224 232 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">M. bovis</named-content>
###xml 286 289 282 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 280 289 276 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>+/+</sup></italic>
###xml 330 336 326 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 337 338 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 336 339 332 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 424 430 420 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 431 432 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 430 433 426 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 453 461 449 457 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">M. bovis</named-content>
###xml 532 538 528 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 539 540 535 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 538 541 534 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 740 746 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 747 748 731 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 746 749 730 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 872 878 856 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 879 880 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 878 881 862 865 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 986 994 966 974 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">M. bovis</named-content>
###xml 1186 1192 1162 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1193 1194 1169 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</italic>
###xml 1192 1195 1168 1171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;<italic>/</italic>&#8722;</sup>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 55 67 <span type="species:ncbi:33892">M. bovis BCG</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 228 240 <span type="species:ncbi:33892">M. bovis BCG</span>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 434 438 <span type="species:ncbi:10090">mice</span>
###xml 453 465 <span type="species:ncbi:33892">M. bovis BCG</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 551 556 <span type="species:ncbi:9606">human</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 750 754 <span type="species:ncbi:10090">mice</span>
###xml 783 787 <span type="species:ncbi:10090">mice</span>
###xml 882 886 <span type="species:ncbi:10090">mice</span>
###xml 962 966 <span type="species:ncbi:10090">mice</span>
###xml 986 998 <span type="species:ncbi:33892">M. bovis BCG</span>
###xml 1196 1200 <span type="species:ncbi:10090">mice</span>
Ifngr1-/- mice, the researchers report, cannot control M. bovis BCG infections and do not form mature granulomas just like human patients with IFN-gammaR1 deficiency. Wild-type C57BL/6 (Ifngr1+/+) mice, however, rapidly control M. bovis BCG infections and form mature granulomas. Ifngr1+/+ HSC transplanted into mycobacteria-free Ifngr1-/- mice survived well and protected the mice against later mycobacterial challenge but Ifngr1-/- mice infected with M. bovis BCG before HSCT rejected the transplanted HSCs. Mycobacteria-infected Ifngr1-/- mice and human patients with IFN-gammaR1 deficiency have blood high levels of IFN-gamma. Could this be responsible for HSCT rejection? To find out, the researchers expressed IFN-gamma in uninfected Ifngr1-/- mice before HSCT. As in infected mice, these grafts failed. Conversely, transplanted HSCs survived when transplanted into Ifngr1-/- mice that had been genetically altered to express no IFN-gamma, even when these mice were infected with M. bovis BCG before transplantation. Finally, when the researchers used antibodies (proteins made by the immune system that recognize specific molecules) to remove circulating IFN-gamma from infected Ifngr1-/- mice, HSCT worked well in the animals with the lowest IFN-gamma levels.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 441 447 <span type="species:ncbi:9606">people</span>
###xml 581 586 <span type="species:ncbi:9606">human</span>
###xml 647 655 <span type="species:ncbi:9606">patients</span>
###xml 974 978 <span type="species:ncbi:10090">mice</span>
###xml 986 991 <span type="species:ncbi:9606">human</span>
These findings indicate that in a mouse model of IFN-gammaR1 deficiency, high circulating IFN-gamma concentrations drive the rejection of transplanted HSCs and prevent the development of antimycobacterial immunity, probably by directly killing the transplanted cells and/or stopping them multiplying. They also suggest how HSCT could be improved in patients with IFN-gammaR1 deficiency although, as with all animal studies, the situation in people might turn out to be very different. Importantly, antibodies that reduce circulating IFN-gamma are already being used to treat other human immune diseases, so the clinical use of these antibodies in patients with IFN-gamma deficiency before HSCT is feasible. Finally, the researchers speculate that the use of IFN-gamma-depleting antibodies might be beneficial in other situations where HSCT often fails such as when a close relative is not available as a donor. However, this possibility will need to be thoroughly tested in mice before human clinical trials can be started.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
###xml 74 79 <span type="species:ncbi:9606">Child</span>
###xml 91 96 <span type="species:ncbi:9606">Human</span>
General information about  is available from the US National Institute of Child Health and Human Development
###end p 19
###begin p 20
###xml 32 35 <span type="species:ncbi:9606">Man</span>
###xml 37 41 <span type="species:ncbi:9606">OMIM</span>
Online Mendelian Inheritance in Man (OMIM) provides information about
###end p 20
###begin p 21
Wikipedia has pages on  and on  (note that Wikipedia is a free online encyclopedia that anyone can edit; available in several languages)
###end p 21
###begin p 22
###xml 88 94 <span type="species:ncbi:9606">humans</span>
 focuses on the genetic basis of predicposition or resistance to infectious diseases in humans
###end p 22
###begin title 23
Introduction
###end title 23
###begin p 24
###xml 271 272 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b001">1</xref>
###xml 273 274 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b003">3</xref>
###xml 347 348 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b004">4</xref>
###xml 349 350 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b005">5</xref>
###xml 455 456 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b006">6</xref>
###xml 661 680 637 656 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Mycobacterium bovis</named-content>
###xml 753 754 729 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b007">7</xref>
###xml 773 774 749 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b003">3</xref>
###xml 826 841 802 817 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">M. tuberculosis</named-content>
###xml 843 844 819 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b007">7</xref>
###xml 845 846 821 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b008">8</xref>
###xml 968 969 944 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b009">9</xref>
###xml 1049 1050 1025 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b007">7</xref>
###xml 1051 1053 1027 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b010">10</xref>
###xml 1217 1219 1193 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b011">11</xref>
###xml 1409 1410 1385 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b007">7</xref>
###xml 661 680 <span type="species:ncbi:1765">Mycobacterium bovis</span>
###xml 707 710 <span type="species:ncbi:33892">BCG</span>
###xml 777 783 <span type="species:ncbi:9606">Humans</span>
###xml 826 841 <span type="species:ncbi:1773">M. tuberculosis</span>
###xml 958 966 <span type="species:ncbi:9606">patients</span>
###xml 1039 1047 <span type="species:ncbi:9606">patients</span>
###xml 1056 1062 <span type="species:ncbi:9606">Humans</span>
###xml 1322 1330 <span type="species:ncbi:9606">patients</span>
Complete deficiency of the ligand-binding chain of the interferon-gamma receptor (IFN-gammaR1) is an autosomal recessive disorder described in 1996 as the first genetic aetiology of the syndrome of Mendelian Susceptibility to Mycobacterial Diseases ("MSMD": MIM 209950) [1-3]. Causal mutations either abrogate cell surface IFN-gammaR1 expression [4,5] or prevent IFN-gamma recognition due to the production of surface-expressed, non-functional receptors [6]. Both types of IFN-gammaR1 deficiency result in a complete loss of cellular responses to IFN-gamma. This disorder confers a profound and selective susceptibility to weakly virulent mycobacteria, such as Mycobacterium bovis bacillus Calmette Guerin (BCG) vaccines and environmental mycobacteria [7], as reviewed in [3]. Humans are also susceptible to the more virulent M. tuberculosis [7,8]. Other infectious diseases are rare, with the exception of salmonellosis, which has been diagnosed in several patients [9]. Listeriosis and a few viral diseases were each diagnosed in single patients [7,10]. Humans do not produce mature granulomas in response to mycobacteria, and instead display poorly delimited, poorly differentiated, multibacillary tissue lesions [11]. They present with early-onset, disseminated, recurrent, and multiple mycobacterial infections. Most patients die in early childhood, with only one-third surviving to the age of 15 years [7].
###end p 24
###begin p 25
###xml 90 91 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b003">3</xref>
###xml 92 93 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b007">7</xref>
###xml 647 649 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b012">12</xref>
###xml 765 767 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b013">13</xref>
###xml 768 770 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b015">15</xref>
###xml 1167 1169 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b015">15</xref>
###xml 1245 1247 1221 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b013">13</xref>
###xml 1248 1250 1224 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b015">15</xref>
###xml 1464 1466 1440 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b016">16</xref>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
###xml 778 786 <span type="species:ncbi:9606">patients</span>
###xml 837 845 <span type="species:ncbi:9606">patients</span>
###xml 988 996 <span type="species:ncbi:9606">patients</span>
The treatment of patients with complete IFN-gammaR1 deficiency is particularly difficult [3,7]. Antibiotics alone do not achieve permanent clinical remission. Unlike patients with other MSMD aetiologies, those with complete IFN-gammaR1 (or IFN-gammaR2) deficiency do not benefit from exogenous IFN-gamma administration, owing to the lack of a specific receptor. The remission of mycobacterial infection following the first case of haematopoietic stem cell transplantation (HSCT) in such an individual provided proof-of-principle that IFN-gammaR1 deficiency is primarily a haematopoietic disorder, despite the ubiquitous expression of IFN-gammaR1 [12]. However, subsequent attempts revealed a very high rate of primary and secondary rejection in HLA-identical HSCT [13-15]. Nine patients received a total of 12 transplants. Four of these patients died within eight months of transplantation-from mycobacterial disease in two cases-and three individuals rejected the graft. Two of the five patients who survived presented only very low levels of chimerism and no chimerism was observed in a third. One individual had a low-grade infection at the time of the treatment [15]. Only three individuals have remained free from infectious complications [13,15] and are currently healthy, nine, seven, and seven years after HSCT. This rate of HLA-identical graft rejection is by far the highest reported for HSCT to treat primary immunodeficiencies or congenital disorders [16]. These observations indicate that HSCT is potentially curative in IFN-gammaR1-deficient individuals, but associated with a particularly high and unexplained rate of graft rejection, resulting in unacceptable morbidity and mortality rates.
###end p 25
###begin p 26
###xml 58 61 54 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 52 61 48 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 79 82 71 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 75 82 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 100 103 92 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 94 103 86 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 110 113 102 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 106 113 98 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 116 118 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b017">17</xref>
###xml 119 121 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b018">18</xref>
###xml 283 285 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b017">17</xref>
###xml 286 288 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b019">19</xref>
###xml 289 291 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b023">23</xref>
###xml 315 318 303 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 309 318 297 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 372 387 360 375 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">M. tuberculosis</named-content>
###xml 389 391 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b024">24</xref>
###xml 392 394 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b025">25</xref>
###xml 397 405 385 393 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">M. avium</named-content>
###xml 407 409 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b026">26</xref>
###xml 420 422 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b027">27</xref>
###xml 431 434 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 425 434 413 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 500 501 488 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 514 515 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</italic>
###xml 562 564 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b027">27</xref>
###xml 642 643 626 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b007">7</xref>
###xml 847 848 831 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b004">4</xref>
###xml 849 851 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b011">11</xref>
###xml 909 912 893 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 905 912 889 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 937 939 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b018">18</xref>
###xml 984 987 968 971 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 978 987 962 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 372 387 <span type="species:ncbi:1773">M. tuberculosis</span>
###xml 397 405 <span type="species:ncbi:1764">M. avium</span>
###xml 415 418 <span type="species:ncbi:33892">BCG</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 511 514 <span type="species:ncbi:33892">BCG</span>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
###xml 567 570 <span type="species:ncbi:33892">BCG</span>
###xml 681 689 <span type="species:ncbi:9606">patients</span>
###xml 748 751 <span type="species:ncbi:33892">BCG</span>
###xml 913 917 <span type="species:ncbi:10090">mice</span>
###xml 932 935 <span type="species:ncbi:33892">BCG</span>
###xml 988 992 <span type="species:ncbi:10090">mice</span>
###xml 1032 1035 <span type="species:ncbi:33892">BCG</span>
###xml 1062 1067 <span type="species:ncbi:9606">human</span>
###xml 1092 1096 <span type="species:ncbi:10090">mice</span>
###xml 1204 1210 <span type="species:ncbi:9606">humans</span>
We used mice selectively deficient in IFN-gamma R1 (Ifngr1-/-), IFN-gamma (Ifng-/-), or both (Ifngr1-/- x Ifng-/-) [17,18], as a means of investigating the mechanism of graft rejection in IFN-gammaR1-deficient patients. These mice are susceptible to several intracellular pathogens [17,19-23]. In particular, Ifngr1-/- mice are highly susceptible to mycobacteria, such as M. tuberculosis [24,25], M. avium [26] and BCG [27]. Ifngr1-/- mice die within nine weeks of the intravenous injection of 2 x 107 cells of BCG, whereas control mice survive such injections [27]. BCG is also the most common pathogen in IFN-gammaR1-deficient individuals [7]. On histological examination, these patients have tissue lesions containing large numbers of acid-fast BCG, with small numbers of structurally impaired granulomas and high tissue loads of mycobacteria [4,11]. The same infectious phenotype has been observed in Ifng-/- mice infected with BCG [18]. Thus, the extreme susceptibility of Ifngr1-/- mice to mycobacterial infections, including BCG in particular, mimics the human condition, making these mice an ideal model for studies of the mechanisms underlying the HSCT failure observed in IFN-gammaR1-deficient humans.
###end p 26
###begin title 27
Materials and Methods
###end title 27
###begin title 28
Animals
###end title 28
###begin p 29
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 30 33 30 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 181 184 181 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 175 184 175 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b017">17</xref>
###xml 240 243 240 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 236 243 236 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b018">18</xref>
###xml 410 413 410 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 404 413 404 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 422 425 422 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 418 425 418 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 542 545 542 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 536 545 536 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 552 555 552 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 548 555 548 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 633 636 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 629 636 629 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 653 656 653 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 647 656 647 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
###xml 657 661 <span type="species:ncbi:10090">mice</span>
###xml 741 745 <span type="species:ncbi:10090">mice</span>
Specific pathogen-free, Ifngr1+/+ C57BL/6 mice were purchased from Charles River (L'Arbresle, France) and used at six to nine weeks of age. Interferon gamma receptor chain 1 (Ifngr1-/-, stock no. 003288, N10) [17] and interferon gamma (Ifng-/-, stock no. 002287, N10) [18] mice were purchased from JaxLab and reared at the CDTA (Centre de Distribution, Typage et Archivage animal, Orleans, France). Both Ifngr1-/- and Ifng-/- mice were backcrossed onto the C57BL/6 background for more than ten generations. Double knock-out (DKO) mice (Ifngr1-/- x Ifng-/-) were generated in a pathogen-free animal facility, by mating homozygous Ifng-/- mice with Ifngr1-/- mice. The resulting F1 animals were then intercrossed to generate double homozygous mice, identified by PCR on tail DNA (primers and conditions available from the JaxLab Web site [ and ]). All experiments and procedures were performed in accordance with French Ministry of Agriculture regulations for animal experimentation (1987) and the guidelines of our institution's animal welfare committee.
###end p 29
###begin title 30
Haematopoietic Stem Cell Transfer
###end title 30
###begin p 31
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 327 331 <span type="species:ncbi:10090">mice</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
###xml 541 545 <span type="species:ncbi:10090">mice</span>
###xml 727 731 <span type="species:ncbi:10090">Mice</span>
Recipient mice were subjected to intensive or milder doses (550 rads to 1,200 rads) of body irradiation, using a Cs137 radioactive source (Pasteur Institute). Immune reconstitution was then initiated by the intravenous administration, via a lateral tail vein, of two million total bone marrow cells freshly isolated from donor mice. Briefly, bone marrow cells were flushed into PBS from the femurs and tibias of donor mice. Red blood cells were lysed and the remaining cells were counted before bone marrow cell transfer. After engraftment, mice were kept in a specific-pathogen-free animal facility, in filter-topped cages in an isolation room. All caging procedures and manipulations were carried out in a laminar flow hood. Mice were used for experimental infection eight weeks after HSCT.
###end p 31
###begin title 32
Analysis of Chimerism and Reconstitution
###end title 32
###begin p 33
The extent of haematopoietic reconstitution by the donor phenotype was assessed every two weeks, during the eight weeks before experimental infection, using specific antibodies. Immunofluorescence analyses were carried out on whole blood. Briefly, donor bone marrow cells expressed the Ly5.1 marker, whereas recipient leukocytes expressed the Ly5.2 marker. Chimerism was therefore assessed as the percentage of cells expressing the Ly5.1 isotype (engraftment). Antibodies against the following surface antigens (all from BD Bioscience Pharmingen) were used, as FITC or PE conjugates, to evaluate peripheral reconstitution: TCRalphabeta, B220, Mac-1 and GR1. Blood (25 mul) was first blocked with 24G2 serum, then stained with specific antibodies. Red blood cells were then lysed with PharM Lyse buffer and flow cytometry was carried out on the remaining cells (FACScan, Becton Dickinson).
###end p 33
###begin title 34
###xml 28 31 <span type="species:ncbi:33892">BCG</span>
Experimental Infection with BCG and Determination of the Number of Colony-Forming Units
###end title 34
###begin p 35
###xml 24 25 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 36 38 36 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b028">28</xref>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b029">29</xref>
###xml 331 333 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b029">29</xref>
###xml 856 857 843 844 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 3 <span type="species:ncbi:33892">BCG</span>
###xml 41 44 <span type="species:ncbi:33892">BCG</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
BCG strain Pasteur 1173P2 was used [28]. BCG was prepared as described elsewhere [29], frozen in aliquots and stored at -80 degreesC. For each infection experiment, groups of non-irradiated animals were included as positive and negative controls of infection. Bacteria were counted in the spleen and liver, as described elsewhere [29]. In brief, blood samples were taken from six to eight mice for each point. The mice were then killed, and their organs were dissected out, placed in 2 ml screw-cap tubes filled with sterile water and homogenized with a 5 mm stainless steel ball (SKF) using a mini-8 bead-beater (Biospec). Spots (50 mul) of serial five-fold dilutions of this suspension were plated on Middlebrook 7H11 medium supplemented with OADC (Difco). The plates were incubated for 20 d at 37 degreesC, under a humidified atmosphere containing 5% CO2, and colonies were counted using a stereoscopic binocular microscope with a detection threshold of 170 CFU per organ.
###end p 35
###begin title 36
ELISA
###end title 36
###begin p 37
###xml 165 170 <span type="species:ncbi:10090">Mouse</span>
Serum was recovered from whole blood samples following coagulation. Serum aliquots were frozen at -20 degreesC for quantitative sandwich immunoassays for IFN-gamma. Mouse ELISA kits from R&D Systems were used, according to the manufacturer's recommendations, in all experiments. The detection limit of the kit was less than 2 pg/ml.
###end p 37
###begin title 38
RNA Purification and Northern Blot Analysis
###end title 38
###begin p 39
###xml 607 609 590 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 507 513 <span type="species:ncbi:10090">murine</span>
Tissue samples were lysed in 1 ml of Trizol (Invitrogen) and the resulting suspensions were immediately frozen and stored at -80 degreesC. Total RNA was extracted with a kit based on the acid phenol-guanidine method, according to the manufacturer's instructions. Total RNA concentration was estimated by spectrophotometry. Total RNA (15 mug in 50% formamide) was blotted onto a nylon membrane. The membrane was incubated for three hours at 80 degreesC and was then washed in 2xSSC before hybridisation with murine IFN-gamma and GAPDH probes generated by PCR (primers available on request) and labelled with 32P by random priming. Each autoradiograph was densitometrically scanned and levels of the specific IFN-gamma transcripts were normalised with respect to GAPDH transcript levels.
###end p 39
###begin title 40
Preparation and Use of Recombinant Adeno-Associated Vectors and Injection
###end title 40
###begin p 41
###xml 283 285 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b030">30</xref>
###xml 430 432 418 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 485 487 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b031">31</xref>
###xml 563 565 547 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sup>
###xml 666 669 649 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 660 669 643 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 812 816 791 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lacZ</italic>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
The mouse IFN-gamma cDNA was amplified by PCR from the L929 cell line and inserted into convenient restriction sites in the pGG1 vector. The resulting plasmid was sequenced to check the integrity of the mIFN-gamma cDNA. We prepared rAAV-IFN-gamma particles, as previously described [30], by a helper-virus-free method involving the triple transfection of HEK 293 cells. Physical particles were estimated by dot plots, and 1.7 x 1012 such particles were obtained per ml of preparation [31]. We assessed rAAV-IFN-gamma particle function in vivo, by injecting 5 x 1010 rAAV particles, in a final volume of 100 mul, into the left gastrocnemius muscle of recipient Ifngr1-/- mice. Serum samples were recovered at various time points after injection and mIFN-gamma was quantified by ELISA. A rAAV vector including the lacZ gene was used as negative control.
###end p 41
###begin title 42
Antibody-Mediated Cytokine Neutralisation
###end title 42
###begin p 43
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 189 191 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b032">32</xref>
###xml 264 266 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b033">33</xref>
###xml 413 423 409 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium</italic>
###xml 435 437 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b034">34</xref>
###xml 632 635 628 631 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 626 635 622 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>+/+</sup></italic>
###xml 38 41 <span type="species:ncbi:33892">BCG</span>
###xml 142 145 <span type="species:ncbi:10116">rat</span>
###xml 151 156 <span type="species:ncbi:10090">mouse</span>
###xml 217 220 <span type="species:ncbi:10116">rat</span>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
###xml 398 403 <span type="species:ncbi:10090">mouse</span>
###xml 513 516 <span type="species:ncbi:10116">rat</span>
###xml 676 680 <span type="species:ncbi:10090">mice</span>
Animals were infected with 106 CFU of BCG. Fourteen days later, they received an intraperitoneal injection of a mixture of 0.8 mg of purified rat anti-mouse IFN-gamma antibody (clone XMG1 [32]) and 0.8 mg of purified rat anti-mouse IL-12p40 antibody (clone C15-1 [33]). Antibodies were purified from the culture supernatant by ammonium sulphate precipitation and shown to function effectively in a mouse model of Plasmodium infection [34]. The control group received an injection of 1.6 mg of irrelevant purified rat IgG antibody (Sigma). In all groups, the injection was repeated on days 15, 17, 20, and 24. Bone marrow from Ifngr1+/+ donors was transferred to the recipient mice 23 d after sublethal body irradiation (550 rad). Serum IFN-gamma concentration and chimerism were monitored throughout the experiment.
###end p 43
###begin title 44
Histology
###end title 44
###begin p 45
Organs were fixed by immersion for 24 h in 3.7% formaldehyde and were then transferred to 70% ethanol for 24 h to 48 h before embedding in paraffin. Sections (5 mum) were cut on a rotary microtome, stretched in a water bath, mounted on glass slides and stained with haematoxylin-eosin-saffron (HES) or by the Zielh-Neelsen method.
###end p 45
###begin title 46
Results
###end title 46
###begin title 47
###xml 6 9 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 10 14 <span type="species:ncbi:10090">Mice</span>
###xml 34 37 <span type="species:ncbi:33892">BCG</span>
Ifngr1-/- Mice Are Susceptible to BCG Infection
###end title 47
###begin p 48
###xml 14 17 14 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 8 17 8 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 103 104 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 110 118 108 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g001">Figure 1</xref>
###xml 205 206 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 281 287 275 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 287 290 281 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 462 470 456 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g001">Figure 1</xref>
###xml 515 516 509 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 537 538 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 550 553 544 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 544 553 538 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 582 583 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 695 697 687 689 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 745 747 737 739 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 770 778 762 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g001">Figure 1</xref>
###xml 785 791 777 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 791 794 783 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 907 909 899 901 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 975 978 967 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 969 978 961 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1018 1021 1010 1013 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1012 1021 1004 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1107 1113 1099 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1113 1116 1105 1108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1241 1247 1233 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1247 1250 1239 1242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1378 1381 1370 1373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1372 1381 1364 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1574 1580 1566 1572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1580 1583 1572 1575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1732 1734 1720 1722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b011">11</xref>
###xml 1768 1771 1756 1759 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1762 1771 1750 1759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1803 1811 1791 1799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M. bovis</italic>
###xml 1861 1863 1849 1851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b027">27</xref>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 46 49 <span type="species:ncbi:33892">BCG</span>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
###xml 591 594 <span type="species:ncbi:33892">BCG</span>
###xml 795 799 <span type="species:ncbi:10090">mice</span>
###xml 805 808 <span type="species:ncbi:33892">BCG</span>
###xml 956 959 <span type="species:ncbi:33892">BCG</span>
###xml 979 983 <span type="species:ncbi:10090">mice</span>
###xml 1022 1026 <span type="species:ncbi:10090">mice</span>
###xml 1125 1129 <span type="species:ncbi:10090">mice</span>
###xml 1251 1254 <span type="species:ncbi:33892">BCG</span>
###xml 1264 1268 <span type="species:ncbi:10090">mice</span>
###xml 1382 1386 <span type="species:ncbi:10090">mice</span>
###xml 1592 1596 <span type="species:ncbi:10090">mice</span>
###xml 1693 1701 <span type="species:ncbi:9606">patients</span>
###xml 1772 1776 <span type="species:ncbi:10090">mice</span>
###xml 1803 1815 <span type="species:ncbi:33892">M. bovis BCG</span>
###xml 1933 1939 <span type="species:ncbi:9606">humans</span>
C57BL/6 Ifngr1-/- mice were unable to control BCG infection following intravenous injection with >/= 102 CFU (Figure 1A). Deficient animals survived 29 +/- 2 weeks (mean +/- SD) following challenge with 102 CFU, whereas no mortality was observed in wild-type C57BL/6 control mice (Ifngr1+/+) during 12 mo of follow-up, even after infection with the highest counts of CFU. The survival of deficient animals was inversely proportional to the size of the inoculum (Figure 1A), with mortality ranging from 29 wk with 102 CFU to 12 wk with 106 CFU. Ifngr1-/- mice challenged i.v. with 106 CFU of BCG were unable to control the infection: the bacterial load in the spleen increased to 7.4 +/- 0.3 (Log10 CFU) by 45 d after infection and exceeded 8 Log10 CFU in dying animals (Figure 1B). In Ifngr1+/+ mice, the BCG burden was controlled, with a decrease in CFU observed by day 45, and CFU numbers falling to 5 Log10 by day 90. Granuloma formation was altered in BCG-infected Ifngr1-/- mice. Two weeks after infection, Ifngr1-/- mice had fewer and smaller granulomas in both the spleen and the liver than infected Ifngr1+/+ control mice. Granulomas were mostly lymphoid, with no recruitment of epithelioid cells, whereas the granulomas observed in Ifngr1+/+ BCG-infected mice contained mostly epithelioid cells and a few lymphocytes (unpublished data). By day 90 post-infection, Ifngr1-/- mice presented massive mycobacterial dissemination associated with large necrotising granulomas. In contrast, a very small number of small, well-delimited granulomas were observed in infected Ifngr1+/+ control mice (unpublished data). These data are consistent with the absence of mature granulomas observed in patients entirely lacking IFN-gammaR1 [11]. Our results confirm that Ifngr1-/- mice are highly susceptible to M. bovis BCG infection, consistent with previous reports [27], and validate this model for the study of IFN-gammaR1 deficiency in humans.
###end p 48
###begin title 49
###xml 6 9 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 10 14 <span type="species:ncbi:10090">Mice</span>
###xml 34 37 <span type="species:ncbi:33892">BCG</span>
Ifngr1-/- Mice Are Susceptible to BCG Infection
###end title 49
###begin p 50
###xml 10 13 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 65 68 <span type="species:ncbi:33892">BCG</span>
(A) Ifngr1-/- mice were infected with between 102 and 106 CFU of BCG, and animal survival (five animals per group) was monitored thereafter.
###end p 50
###begin p 51
###xml 92 95 92 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 86 95 86 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 105 108 105 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 100 108 100 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
(B) Splenic mycobacterial loads were determined on days 4, 15, 45, and 90 in infected Ifngr1-/- and Ifngr+/+ mice; means of five animals per point are shown.
###end p 51
###begin title 52
###xml 51 54 51 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 45 54 45 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 55 59 <span type="species:ncbi:10090">Mice</span>
HSCT Restores Anti-Mycobacterial Immunity in Ifngr1-/- Mice
###end title 52
###begin p 53
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 21 30 21 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 93 96 93 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 543 551 543 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g002">Figure 2</xref>
###xml 709 710 709 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 800 803 800 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 794 803 794 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 836 839 836 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 830 839 830 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 895 901 895 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 901 904 901 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 929 932 929 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 923 932 923 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 946 954 946 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g002">Figure 2</xref>
###xml 964 967 964 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 958 967 958 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 986 992 986 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 992 995 992 995 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1051 1057 1051 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1057 1060 1057 1060 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1076 1082 1076 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1082 1085 1082 1085 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1121 1129 1121 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g002">Figure 2</xref>
###xml 1266 1274 1266 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g002">Figure 2</xref>
###xml 1381 1389 1381 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g002">Figure 2</xref>
###xml 1789 1791 1777 1779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b012">12</xref>
###xml 1792 1794 1780 1782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b013">13</xref>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 294 300 <span type="species:ncbi:9606">humans</span>
###xml 620 624 <span type="species:ncbi:10090">mice</span>
###xml 636 639 <span type="species:ncbi:33892">BCG</span>
###xml 718 721 <span type="species:ncbi:33892">BCG</span>
###xml 755 758 <span type="species:ncbi:33892">BCG</span>
###xml 875 878 <span type="species:ncbi:33892">BCG</span>
###xml 1061 1065 <span type="species:ncbi:10090">mice</span>
###xml 1101 1105 <span type="species:ncbi:10090">mice</span>
###xml 1340 1343 <span type="species:ncbi:33892">BCG</span>
###xml 1564 1567 <span type="species:ncbi:33892">BCG</span>
###xml 1604 1608 <span type="species:ncbi:10090">mice</span>
###xml 1773 1778 <span type="species:ncbi:9606">human</span>
###xml 1779 1787 <span type="species:ncbi:9606">patients</span>
We subjected C57BL/6 Ifngr1-/- mice to HSCT with sex- and age-matched syngenic C57BL/6 Ifngr1+/+ donors with an intensive total body irradiation conditioning regimen (1,200 rad). Several doses of bone marrow were tested and we found that 2 million cells was the dose most comparable to HSCT in humans. Leukocyte chimerism was complete, with low levels of residual autologous cells nine wk after treatment. Peripheral reconstitution was achieved, with the expected counts of lymphoid (T and B) and myeloid (macrophages and granulocytes) cells (Figure 2A, unpublished data). We then evaluated the ability of the recipient mice to control BCG infection. Ten weeks after HSCT, animals were challenged i.v. with 106 CFU of BCG. They were killed 45 d later and BCG load in the spleen was determined. Ifngr1-/- animals transplanted with Ifngr1-/- bone marrow were unable to control BCG infection, like Ifngr1+/+ animals receiving Ifngr1-/- bone marrow (Figure 2B). Ifngr1-/- animals receiving Ifngr1+/+ bone marrow controlled the infection as efficiently as Ifngr1+/+ mice receiving Ifngr1+/+ bone marrow or mice with no graft (Figure 2B). HSCT recipients conditioned with a milder regimen (550 rads) displayed mixed chimerism, with only about 50% donor Ly5.1 lymphocytes (Figure 2C). The donor haematopoietic compartment had nonetheless restored BCG growth control 45 d after infection (Figure 2D). Thus, the restoration of IFN-gammaR1 expression in the haematopoietic compartment alone, even in only a fraction of the compartment, is sufficient to confer resistance to BCG infection. Mycobacterial disease in mice with IFN-gammaR1 deficiency therefore results from the specific absence of IFN-gammaR1 in the haematopoietic compartment, consistent with reported data for HSCT in human patients [12,13].
###end p 53
###begin title 54
###xml 51 54 51 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 45 54 45 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 55 59 <span type="species:ncbi:10090">Mice</span>
HSCT Restores Anti-Mycobacterial Immunity in Ifngr1-/- Mice
###end title 54
###begin p 55
###xml 10 13 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 23 26 23 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 135 138 135 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 130 138 130 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
(A) Ifngr1-/- and Ifngr+/+ mice (five animals per group) expressing the Ly5.2 marker were subjected to HSCT with bone marrow from Ifngr+/+ mice expressing the Ly5.1 marker, after intense irradiation (1,200 rads). Chimerism, assessed by determining the surface expression of Ly5.1 and Ly5.2 on lymphocytes, and peripheral reconstitution, assessed by determining the surface expression of TCRalphabeta and B220 markers on lymphocytes, were analysed by flow cytometry nine weeks after HSCT treatment.
###end p 55
###begin p 56
###xml 10 13 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 23 26 23 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 77 86 77 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 95 98 95 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 90 98 90 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 147 150 <span type="species:ncbi:33892">BCG</span>
(B) Ifngr1-/- and Ifngr+/+ mice were subjected to HSCT with bone marrow from Ifngr1-/- or Ifngr+/+ mice. HSCT-treated mice were then infected with BCG and bacterial loads were determined 45 d later (five animals per group).
###end p 56
###begin p 57
###xml 10 13 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 23 26 23 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 110 113 110 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 105 113 105 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
(C) Ifngr1-/- and Ifngr+/+ mice expressing the Ly5.2 marker were subjected to HSCT with bone marrow from Ifngr+/+ mice expressing the Ly5.1 marker, after mild irradiation (550 rads). Chimerism and peripheral reconstitution were analysed by flow cytometry nine weeks after HSCT treatment.
###end p 57
###begin p 58
###xml 10 13 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 23 26 23 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 140 143 <span type="species:ncbi:33892">BCG</span>
(D) Ifngr1-/- and Ifngr+/+ mice were subjected to HSCT with bone marrow from Ifngr+/+ mice after intense or mild irradiation, infected with BCG and bacterial load was determined 45 d later.
###end p 58
###begin title 59
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 21 30 21 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 31 35 <span type="species:ncbi:10090">Mice</span>
###xml 61 64 <span type="species:ncbi:33892">BCG</span>
Rejection of HSCT in Ifngr1-/- Mice Previously Infected with BCG
###end title 59
###begin p 60
###xml 156 158 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b012">12</xref>
###xml 159 161 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b015">15</xref>
###xml 217 220 213 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 211 220 207 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 225 231 221 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 231 234 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 275 276 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 354 360 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 360 363 356 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 427 430 423 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 421 430 417 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 435 441 431 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 441 444 437 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 511 517 507 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 517 520 513 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 711 713 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b012">12</xref>
###xml 714 716 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b015">15</xref>
###xml 725 728 721 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 719 728 715 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 960 968 956 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g003">Figure 3</xref>
###xml 994 1000 990 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1000 1003 996 999 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1054 1060 1050 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1060 1063 1056 1059 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1241 1243 1237 1239 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 1272 1275 1268 1271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1266 1275 1262 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1303 1305 1299 1301 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 1313 1319 1309 1315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1319 1322 1315 1318 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1329 1337 1325 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g003">Figure 3</xref>
###xml 1404 1407 1400 1403 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1398 1407 1394 1403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1469 1475 1465 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1475 1478 1471 1474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1519 1522 1515 1518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1513 1522 1509 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 149 154 <span type="species:ncbi:9606">child</span>
###xml 194 197 <span type="species:ncbi:33892">BCG</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 281 284 <span type="species:ncbi:33892">BCG</span>
###xml 445 448 <span type="species:ncbi:33892">BCG</span>
###xml 458 462 <span type="species:ncbi:10090">mice</span>
###xml 648 653 <span type="species:ncbi:9606">human</span>
###xml 665 673 <span type="species:ncbi:9606">patients</span>
###xml 729 733 <span type="species:ncbi:10090">mice</span>
###xml 748 751 <span type="species:ncbi:33892">BCG</span>
###xml 945 948 <span type="species:ncbi:33892">BCG</span>
###xml 1004 1008 <span type="species:ncbi:10090">mice</span>
###xml 1023 1026 <span type="species:ncbi:33892">BCG</span>
###xml 1323 1327 <span type="species:ncbi:10090">mice</span>
###xml 1523 1527 <span type="species:ncbi:10090">mice</span>
###xml 1542 1545 <span type="species:ncbi:33892">BCG</span>
###xml 1637 1645 <span type="species:ncbi:9606">patients</span>
All the IFN-gammaR1-deficient patients undergoing HSCT had a history of mycobacterial disease, as HSCT has not yet been attempted in an asymptomatic child [12-15]. We thus infected animals with BCG before HSCT. Ifngr1-/- and Ifngr1+/+ mice were infected intravenously with 106 CFU BCG and subjected to HSCT 40 d later, with sex- and age-matched syngenic Ifngr1+/+ donors. Following intense irradiation (1,200 rads), both Ifngr1-/- and Ifngr1+/+ BCG-infected mice displayed successful immune reconstitution with Ifngr1+/+ bone marrow (unpublished data). However, with a milder conditioning regimen (550 rads) more closely mimicking the situation in human transplant patients in terms of the chimerism post HSCT [12-15], Ifngr1-/- mice infected with BCG before HSCT rejected the graft, with Ly5.1 lymphocytes from the donor phenotype accounting for less than 2% of the circulating cells, whereas about 50% chimerism was observed in the absence of BCG infection (Figure 3A). Serving as a control, Ifngr1+/+ mice infected with BCG and subjected to HSCT with Ifngr1+/+ donor marrow, under the same milder conditioning regimen, displayed successful engraftment and reconstitution. Bacterial loads, determined 11 wk after infection, reached 8.4 Log10 CFU per spleen in the Ifngr1-/- cohort, versus only 4.5 Log10 CFU in Ifngr1+/+ mice (Figure 3B). Histological observations confirmed dissemination in the Ifngr1-/- cohort, contrasting with small, well-delimited granulomas in Ifngr1+/+ animals (unpublished data). Thus, Ifngr1-/- mice infected with BCG reject HSCT, with features mimicking the graft rejection observed in IFN-gammaR1-deficient patients.
###end p 60
###begin title 61
###xml 37 40 37 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 31 40 31 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 41 45 <span type="species:ncbi:10090">Mice</span>
###xml 71 74 <span type="species:ncbi:33892">BCG</span>
Rejection of the HSCT Graft in Ifngr1-/- Mice Previously Infected with BCG
###end title 61
###begin p 62
###xml 113 116 113 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 107 116 107 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 126 129 126 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 121 129 121 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 178 181 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 173 181 173 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 216 219 216 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 210 219 210 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 229 232 229 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 224 232 224 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 233 237 <span type="species:ncbi:10090">mice</span>
###xml 257 260 <span type="species:ncbi:33892">BCG</span>
(A) Chimerism was determined by assessing the surface expression of Ly5.1 (donor cells) on lymphocytes, in Ifngr1-/- and Ifngr+/+ mice treated by HSCT with bone marrow from Ifngr+/+ mice, nine weeks post HSCT. Ifngr1-/- and Ifngr+/+ mice were infected with BCG either before or after HSCT (five animals per group).
###end p 62
###begin p 63
###xml 65 68 65 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 59 68 59 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 78 81 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 73 81 73 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 178 181 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 173 181 173 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 112 115 <span type="species:ncbi:33892">BCG</span>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
(B) Bacterial loads were determined after the treatment of Ifngr1-/- and Ifngr+/+ mice previously infected with BCG (three animals per group), by HSCT with bone marrow from Ifngr+/+ mice.
###end p 63
###begin title 64
HSCT Graft Rejection Is Associated with High Serum IFN-gamma Levels
###end title 64
###begin p 65
###xml 91 93 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b035">35</xref>
###xml 159 162 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 153 162 141 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 167 173 155 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 173 176 161 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 351 354 335 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 345 354 329 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 395 397 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b036">36</xref>
###xml 449 455 429 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 455 458 435 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 465 473 445 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g004">Figure 4</xref>
###xml 546 549 522 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 540 549 516 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 554 560 530 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 560 563 536 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 694 697 666 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 688 697 660 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 727 730 699 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 721 730 693 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 775 781 747 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 781 784 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 814 817 786 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 808 817 780 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 831 839 803 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g004">Figure 4</xref>
###xml 946 949 914 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 940 949 908 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 956 964 924 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g004">Figure 4</xref>
###xml 1016 1019 980 983 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1010 1019 974 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1040 1046 1004 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1046 1049 1010 1013 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1066 1072 1030 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1072 1075 1036 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1096 1102 1060 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1102 1105 1066 1069 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1143 1149 1107 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1149 1152 1113 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1162 1170 1126 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g004">Figure 4</xref>
###xml 1218 1226 1182 1190 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">M. bovis</named-content>
###xml 1312 1315 1272 1275 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1306 1315 1266 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1405 1414 1365 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g003">Figures 3</xref>
###xml 1420 1421 1380 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g004">4</xref>
###xml 1548 1551 1504 1507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1542 1551 1498 1507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1628 1634 1580 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1634 1637 1586 1589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1647 1655 1599 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g004">Figure 4</xref>
###xml 1721 1724 1669 1672 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1715 1724 1663 1672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1729 1735 1677 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1735 1738 1683 1686 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1796 1799 1740 1743 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1792 1799 1736 1743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 1854 1857 1794 1797 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1848 1857 1788 1797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1862 1868 1802 1808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1868 1871 1808 1811 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1907 1908 1847 1848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 140 143 <span type="species:ncbi:33892">BCG</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 523 526 <span type="species:ncbi:33892">BCG</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 643 646 <span type="species:ncbi:33892">BCG</span>
###xml 910 913 <span type="species:ncbi:33892">BCG</span>
###xml 950 954 <span type="species:ncbi:10090">mice</span>
###xml 1020 1024 <span type="species:ncbi:10090">mice</span>
###xml 1076 1080 <span type="species:ncbi:10090">mice</span>
###xml 1218 1230 <span type="species:ncbi:33892">M. bovis BCG</span>
###xml 1552 1556 <span type="species:ncbi:10090">mice</span>
###xml 1739 1743 <span type="species:ncbi:10090">mice</span>
###xml 1800 1804 <span type="species:ncbi:10090">mice</span>
###xml 1872 1876 <span type="species:ncbi:10090">mice</span>
###xml 1972 1975 <span type="species:ncbi:33892">BCG</span>
###xml 2044 2050 <span type="species:ncbi:10090">murine</span>
High serum IFN-gamma concentration is a hallmark of human complete IFN-gammaR1 deficiency [35]. We thus monitored serum IFN-gamma levels in BCG-infected Ifngr1-/- and Ifngr1+/+ mice. IFN-gamma was detected as early as 10 d post-infection and its concentration gradually increased towards a plateau at about 6 ng/ml within six wk of infection in Ifngr1-/- mice, confirming previous observations [36]. IFN-gamma remained barely detectable in infected Ifngr1+/+ mice (Figure 4A). Serum IFN-gamma levels, determined 30 d after BCG infection in Ifngr1-/- and Ifngr1+/+ mice previously subjected to HSCT, were found to correlate with the control of BCG infection. IFN-gamma levels were high in Ifngr1-/- animals engrafted with Ifngr1-/- bone marrow and only marginally elevated in Ifngr1+/+ animals engrafted with Ifngr1-/- bone marrow (Figure 4B). In these conditions IFN-gamma levels were very similar to those in BCG-infected non-transplanted Ifngr1-/- mice (Figure 4A). IFN-gamma was almost undetectable in both Ifngr1-/- mice engrafted with Ifngr1+/+ bone marrow and Ifngr1+/+ mice engrafted with Ifngr1+/+ bone marrow, as for non-transplanted Ifngr1+/+ animals (Figure 4B). Following HSCT with mild conditioning after M. bovis BCG infection, IFN-gamma concentration seemed to be high only in the cohort of Ifngr1-/- animals infected at the time of cell transfer, and in such cases, HSCT was unsuccessful (Figures 3A and 4C). These results were confirmed by quantification of IFN-gamma transcripts in the spleens of infected animals. Infected Ifngr1-/- mice contained significantly larger amounts of IFN-gamma mRNA than infected Ifngr1+/+ animals (Figure 4D). Basal levels of IFN-gamma were detected in non-infected Ifngr1-/- and Ifngr1+/+ mice. As expected, no IFN-gamma mRNA was detected in Ifng-/- mice. The amounts of IFN-gamma mRNA in infected Ifngr1-/- and Ifngr1+/+ mice differed by a factor of 2.25 (p </= 0.007). Thus, serum IFN-gamma concentration increased with BCG infection and was inversely correlated with HSCT engraftment in the murine model of IFN-gammaR1 deficiency.
###end p 65
###begin title 66
HSCT Graft Rejection Is Associated with High Serum IFN-gamma Levels
###end title 66
###begin p 67
###xml 68 71 64 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 62 71 58 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 81 84 77 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 76 84 72 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 97 100 <span type="species:ncbi:33892">BCG</span>
(A) IFN-gamma levels were measured over time, in the serum of Ifngr1-/- and Ifngr+/+ mice, after BCG infection (five animals per group).
###end p 67
###begin p 68
###xml 69 72 65 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 63 72 59 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 82 85 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 77 85 73 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 109 112 105 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 103 112 99 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 121 124 117 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 116 124 112 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
(B) IFN-gamma levels were measured after the HSCT treatment of Ifngr1-/- and Ifngr+/+ mice with either Ifngr1-/- or Ifngr+/+ bone marrow (five animals per group).
###end p 68
###begin p 69
###xml 44 47 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 38 47 34 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 57 60 53 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 52 60 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 92 95 88 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 87 95 83 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 127 130 <span type="species:ncbi:33892">BCG</span>
(C) IFN-gamma levels were measured in Ifngr1-/- and Ifngr+/+ mice treated by HSCT with Ifngr+/+ bone marrow, and infected with BCG before or after HSCT (five animals per group).
###end p 69
###begin p 70
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng</italic>
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 81 84 81 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 75 84 75 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 94 97 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 89 97 89 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 295 298 289 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 289 298 283 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 305 308 299 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 300 308 294 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 318 321 312 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 314 321 308 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 114 117 <span type="species:ncbi:33892">BCG</span>
###xml 322 326 <span type="species:ncbi:10090">mice</span>
(D) Northern blot analysis of Ifng and GAPDH mRNA levels in the spleens of Ifngr1-/- and Ifngr+/+ mice 30 d after BCG infection (three animals per group). Spleens were removed from animals, directly frozen in 1 ml of Trizol and stored at -80 degreesC for further preparation. Non-infected Ifngr1-/-, Ifngr+/+, and Ifng-/- mice were used as controls (two animals per group). Means of arbitrary values obtained after scanning were calculated and normalised with respect to the values obtained for GAPDH.
###end p 70
###begin title 71
rAAV-IFN-gamma Injection Promotes Graft Rejection
###end title 71
###begin p 72
###xml 240 242 228 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sup>
###xml 299 302 283 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 293 302 277 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 606 614 574 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g005">Figure 5</xref>
###xml 688 691 656 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 682 691 650 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 865 868 829 832 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 859 868 823 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 955 963 917 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g005">Figure 5</xref>
###xml 988 994 950 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 994 997 956 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1164 1170 1118 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1170 1173 1124 1127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1438 1441 1380 1383 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1432 1441 1374 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1454 1460 1396 1402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 1460 1463 1402 1405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
###xml 665 668 <span type="species:ncbi:33892">BCG</span>
###xml 692 696 <span type="species:ncbi:10090">mice</span>
###xml 754 758 <span type="species:ncbi:10090">mice</span>
###xml 998 1002 <span type="species:ncbi:10090">mice</span>
###xml 1174 1178 <span type="species:ncbi:10090">mice</span>
###xml 1464 1468 <span type="species:ncbi:10090">mice</span>
###xml 1687 1691 <span type="species:ncbi:10090">mice</span>
###xml 1716 1719 <span type="species:ncbi:33892">BCG</span>
We tested the hypothesis that high circulating IFN-gamma levels are responsible for HSCT graft rejection, using a recombinant adeno-associated viral vector encoding IFN-gamma (rAAV-IFN-gamma). Following the intramuscular injection of 5 x 1010 rAAV-IFN-gamma physical particles in non-infected Ifngr1-/- mice, IFN-gamma was secreted ectopically in the muscle and accumulated in the serum (unpublished data), resulting on day 15 in serum IFN-gamma levels ranging from 8 ng/ml to 11 ng/ml. Stable and sustained serum IFN-gamma levels of 6 ng/ml to 7.5 ng/ml were obtained 30 d after rAAV-IFN-gamma injection (Figure 5A), approaching those previously quantitated after BCG infection of Ifngr1-/- mice. HSCT with mild conditioning was thus performed in these mice on day 30 following rAAV-IFN-gamma injection. In these conditions, HSCT graft rejection occurred in Ifngr1-/- recipients, with donor Ly5.1 lymphocytes accounting for only 0.46% +/- 0.1% of cells (Figure 5B). In contrast, control Ifngr1+/+ mice given intramuscular injections of rAAV-IFN-gamma displayed successful engraftment and immune reconstitution. No detectable accumulation of IFN-gamma occurred in Ifngr1+/+ mice, probably because of the rapid clearance of IFN-gamma by IFN-gammaR1-proficient cells. We detected minor increases in the serum levels of cytokines known to be involved in the IL12/23-IFN-gamma circuit (IL12p40 in particular) in both naive and infected Ifngr1-/- and control Ifngr1+/+ mice, at various stages of HSCT, with no repercussions outside this pathway (unpublished data). These data suggest that high circulating IFN-gamma levels at the time of HSCT promote graft rejection in IFN-gammaR1-deficient mice, even in the absence of BCG infection.
###end p 72
###begin title 73
rAAV- IFN-gamma Injection Promotes Graft Rejection
###end title 73
###begin p 74
###xml 77 79 73 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sup>
###xml 138 141 134 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 134 141 130 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 228 231 216 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 222 231 210 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 239 242 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 233 242 221 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>+/+</sup></italic>
###xml 258 261 246 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 252 261 240 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 267 270 255 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 263 270 251 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
(A) A rAAV- IFN-gamma vector was designed, particles were produced and 5 x 1010 physical particles injected into the gastrocnemius of Ifng-/- mice. Serum IFN-gamma levels were determined after rAAV- IFN-gamma injection in Ifngr1-/-, Ifngr1+/+ and DKO (Ifngr1-/-x Ifng-/-) mice (eight animals per group).
###end p 74
###begin p 75
###xml 10 13 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 20 23 20 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 123 126 119 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 118 126 114 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
(B) Ifngr1-/-, Ifngr+/+, and DKO mice were injected with rAAV-IFN-gamma, and HSCT was performed with bone marrow from Ifngr+/+ mice. The percentage chimerism over time was monitored by determining the surface expression of Ly5.1 (donor cells) on lymphocytes (eight animals per group).
###end p 75
###begin p 76
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 95 98 <span type="species:ncbi:33892">BCG</span>
(C) Infected DKO mice showed no HSCT graft rejection. IFN-gamma levels were measured following BCG infection, 30 d after infection (eight animals per group).
###end p 76
###begin p 77
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 32 35 <span type="species:ncbi:33892">BCG</span>
(D) DKO mice were infected with BCG and the percentage chimerism over time was monitored by determining the surface expression of Ly5.1 (donor cells) on lymphocytes (eight animals per group).
###end p 77
###begin title 78
###xml 19 22 19 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 13 22 13 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 29 32 29 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 33 37 <span type="species:ncbi:10090">Mice</span>
Infected DKO Ifngr1-/- x Ifng-/- Mice Show No Graft Rejection after HSCT
###end title 78
###begin p 79
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 41 44 41 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 35 44 35 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 51 54 51 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 225 233 221 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g005">Figure 5</xref>
###xml 333 336 329 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 327 336 323 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 702 708 698 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1</italic>
###xml 708 711 704 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 722 725 718 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 716 725 712 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 763 771 759 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g005">Figure 5</xref>
###xml 957 960 949 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 951 960 943 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1006 1008 998 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sup>
###xml 1134 1142 1118 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g005">Figure 5</xref>
###xml 1269 1277 1251 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g005">Figure 5</xref>
###xml 1322 1325 1300 1303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1316 1325 1294 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 1693 1696 1663 1666 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1687 1696 1657 1666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 30 33 <span type="species:ncbi:33892">BCG</span>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 399 403 <span type="species:ncbi:10090">mice</span>
###xml 483 486 <span type="species:ncbi:33892">BCG</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
###xml 548 551 <span type="species:ncbi:33892">BCG</span>
###xml 743 746 <span type="species:ncbi:33892">BCG</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
###xml 810 814 <span type="species:ncbi:10090">mice</span>
###xml 843 846 <span type="species:ncbi:33892">BCG</span>
###xml 905 908 <span type="species:ncbi:33892">BCG</span>
###xml 923 927 <span type="species:ncbi:10090">mice</span>
###xml 961 965 <span type="species:ncbi:10090">mice</span>
###xml 1055 1059 <span type="species:ncbi:10090">mice</span>
###xml 1207 1211 <span type="species:ncbi:10090">mice</span>
###xml 1326 1330 <span type="species:ncbi:10090">mice</span>
###xml 1393 1396 <span type="species:ncbi:33892">BCG</span>
###xml 1490 1494 <span type="species:ncbi:10090">mice</span>
###xml 1519 1522 <span type="species:ncbi:33892">BCG</span>
###xml 1697 1701 <span type="species:ncbi:10090">mice</span>
When infected with 106 CFU of BCG, Ifngr1-/- x Ifng-/- double knock-out (DKO) mice were unable to control the infection and died within 12 wk of infection (unpublished data). As expected, IFN-gamma was undetectable in serum (Figure 5C). Uninfected DKO mice displayed levels of chimerism after HSCT similar to those observed in Ifngr1-/- mice after total or mild conditioning (unpublished data). DKO mice controlled infection if HSCT with wild-type bone marrow was carried out before BCG infection (unpublished data). We also infected DKO mice with BCG and subjected them to HSCT, as described above. Bone marrow reconstitution was successful, and the level of chimerism obtained was similar to that in Ifngr1+/+ and Ifngr1-/- HSCT-treated and BCG -infected mice (Figure 5D). Successful HSCT in these recipient mice ruled out a direct role for BCG infection, other than through IFN-gamma induction, as the BCG burden in DKO mice was similar to that in Ifngr1-/- mice before cell transfer. We injected 5 x 1010 physical particles of rAAV-IFN-gamma into DKO mice, resulting in high serum IFN-gamma levels (4 ng/ml, 30 d after injection; Figure 5A). Following HSCT, engraftment was almost undetectable in these mice, with a mean of 2.4% (+/- 0.5%) donor Ly5.1 lymphocytes (Figure 5B). Thus, in the absence of IFN-gamma, Ifngr1-/- mice displayed no rejection following HSCT, despite infection with BCG. In contrast, in the presence of high serum levels of IFN-gamma, rejection occurred in these mice, even in the absence of BCG infection. In conclusion, these data clearly support the hypothesis that high circulating IFN-gamma levels are necessary and sufficient for HSCT graft rejection in Ifngr1-/- mice.
###end p 79
###begin title 80
In Vivo Neutralisation of Circulating IFN-gamma Allows HSCT Engraftment
###end title 80
###begin p 81
###xml 191 194 183 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 185 194 177 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 780 788 756 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g006">Figure 6</xref>
###xml 849 852 825 828 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 843 852 819 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 924 932 896 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g006">Figure 6</xref>
###xml 1106 1114 1074 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g006">Figure 6</xref>
###xml 1312 1320 1276 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g006">Figure 6</xref>
###xml 1662 1670 1614 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g006">Figure 6</xref>
###xml 1833 1841 1781 1789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050026-g006">Figure 6</xref>
###xml 2083 2086 2027 2030 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 2077 2086 2021 2030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 407 410 <span type="species:ncbi:33892">BCG</span>
###xml 764 769 <span type="species:ncbi:9606">human</span>
###xml 770 778 <span type="species:ncbi:9606">patients</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
###xml 2087 2091 <span type="species:ncbi:10090">mice</span>
High serum IFN-gamma concentration at the time of HSCT has a deleterious effect on engraftment. We tried to determine whether blood depletion of IFN-gamma could render HSCT of infected Ifngr1-/- mice successful. A first series of experiments was performed with anti-IFN-gamma antibody alone. In these conditions IFN-gamma depletion was not achieved. We thus refined our protocol: animals were infected with BCG and received four intraperitoneal doses of anti-IFN-gamma plus anti-IL-12 antibodies at two-day intervals, starting from day 14, before transplantation on day 23. Another antibody injection was administered on the day after HSCT. IFN-gamma depletion was monitored by blood sampling and HSCT was performed with mild conditioning, mimicking that used for human patients (Figure 6A). The injection of specific antibodies into infected Ifngr1-/- mice kept serum IFN-gamma levels below 0.5 ng/ml before cell transfer (Figure 6B). The injection of isotype control antibodies resulted in a serum IFN-gamma concentration of 1.2 ng/ml at the time of HSCT, and ranging from 3 ng/ml to 5 ng/ml thereafter (Figure 6C). In three of the six animals treated with specific antibodies, serum IFN-gamma levels did not exceed 3 ng/ml in the first week after HSCT and even decreased to 0.1 ng/ml by nine weeks post-HSCT (Figure 6B). Three other animals behaved like the isotype control-treated group, with serum IFN-gamma levels remaining high throughout the experiment. HSCT outcome was found to be strictly correlated with serum IFN-gamma concentration. Chimerism with bone marrow was observed in the three animals in which serum IFN-gamma concentrations remained low (Figure 6D, left). In contrast, the graft was rejected in the three animals in which serum IFN-gamma levels were not controlled; no donor cells were found in such animals (Figure 6D, right). Moreover, bacterial disease was cured in the three animals in which HSCT was successful (unpublished data). Our data therefore demonstrate that efficient IFN-gamma depletion by antibody administration improves engraftment in Ifngr1-/- mice.
###end p 81
###begin title 82
The Depletion of Circulating IFN-gamma Is Sufficient to Allow HSCT Engraftment
###end title 82
###begin p 83
###xml 18 21 18 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifng<sup>&#8722;/&#8722;</sup></italic>
###xml 213 216 209 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 208 216 204 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr<sup>+/+</sup></italic>
###xml 22 26 <span type="species:ncbi:10090">mice</span>
###xml 46 49 <span type="species:ncbi:33892">BCG</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
Groups of six Ifng-/- mice were infected with BCG and injected with a mixture of specific antibodies against IFN-gamma and IL-12 or with a control isotype antibody. HSCT was carried out with bone marrow from Ifngr+/+ mice and serum IFN-gamma levels were monitored over time (A). Data are plotted individually for each animal treated with specific antibodies (B) and control isotype antibodies (C). The percentage chimerism was evaluated and representative FACS analyses are shown for engraftment (D), corresponding to three animals with low serum levels of IFN-gamma (left) and rejection, corresponding to six animals with high serum levels of IFN-gamma (right).
###end p 83
###begin title 84
Discussion
###end title 84
###begin p 85
###xml 399 421 391 413 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Listeria monocytogenes</named-content>
###xml 453 455 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b037">37</xref>
###xml 647 664 631 648 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Toxoplasma gondii</named-content>
###xml 666 668 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b037">37</xref>
###xml 896 898 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b038">38</xref>
###xml 1016 1018 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b039">39</xref>
###xml 1019 1021 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b041">41</xref>
###xml 1334 1336 1298 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b012">12</xref>
###xml 1337 1339 1301 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b015">15</xref>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 194 197 <span type="species:ncbi:33892">BCG</span>
###xml 399 421 <span type="species:ncbi:1639">Listeria monocytogenes</span>
###xml 447 451 <span type="species:ncbi:10090">mice</span>
###xml 647 664 <span type="species:ncbi:5811">Toxoplasma gondii</span>
###xml 860 866 <span type="species:ncbi:10090">murine</span>
###xml 1024 1027 <span type="species:ncbi:33892">BCG</span>
###xml 1228 1234 <span type="species:ncbi:10090">murine</span>
###xml 1271 1279 <span type="species:ncbi:9606">patients</span>
###xml 1380 1383 <span type="species:ncbi:33892">BCG</span>
###xml 1456 1463 <span type="species:ncbi:9606">persons</span>
###xml 1496 1500 <span type="species:ncbi:10090">mice</span>
###xml 1505 1511 <span type="species:ncbi:9606">humans</span>
We have shown that the surface expression of functional IFN-gammaR1 in the haematopoietic compartment alone-actually in only about half of that compartment-is sufficient to protect mice against BCG infection. Similarly, Yap and Sher previously showed that IFN-gammaR1 expression in the haematopoietic compartment was sufficient to restore resistance to the intracellular macrophage-tropic bacterium Listeria monocytogenes in IFN-gammaR1-deficient mice [37]. However, they also showed that IFN-gammaR1 expression on both haematopoietic and non-haematopoietic cells was required to confer resistance to the macrophage-tropic intracellular protozoon Toxoplasma gondii [37]. Consistent with these findings, Dal Canto and Virgin showed that IFN-gamma acted directly on both haematopoietic and non-haematopoietic cells during infection with the medial smooth muscle murine tropic gamma-herpesvirus-68 [38]. Thus, despite the almost ubiquitous expression of IFN-gammaR1 on both haematopoietic and non-haematopoietic cells [39-41], BCG infection can be controlled-as attested by bacterial killing, granuloma structure, and animal survival-by the restricted action of IFN-gamma on the haematopoietic compartment. Results obtained in our murine model are consistent with data from patients with complete IFN-gammaR1 deficiency undergoing HSCT [12-15] and demonstrate that susceptibility to BCG, and by extension to other mycobacteria, is a haematopoietic disease in persons with IFN-gammaR1 deficiency. In mice and humans, the extra-haematopoietic expression of IFN-gammaR1 is redundant for anti-mycobacterial protective immunity.
###end p 85
###begin p 86
###xml 247 250 239 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 241 250 233 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ifngr1<sup>&#8722;/&#8722;</sup></italic>
###xml 709 711 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b042">42</xref>
###xml 712 714 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b043">43</xref>
###xml 952 954 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b044">44</xref>
###xml 1113 1115 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b044">44</xref>
###xml 1116 1118 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b045">45</xref>
###xml 1294 1296 1254 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b046">46</xref>
###xml 1577 1579 1529 1531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b047">47</xref>
###xml 1703 1705 1651 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b048">48</xref>
###xml 1706 1708 1654 1656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b049">49</xref>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 27 33 <span type="species:ncbi:9606">humans</span>
###xml 251 255 <span type="species:ncbi:10090">mice</span>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 684 689 <span type="species:ncbi:9606">human</span>
###xml 1147 1152 <span type="species:ncbi:9606">human</span>
###xml 1318 1323 <span type="species:ncbi:10090">mouse</span>
###xml 1361 1376 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 1855 1859 <span type="species:ncbi:10090">mice</span>
###xml 1864 1870 <span type="species:ncbi:9606">humans</span>
Likewise, in both mice and humans, the rate of HSCT graft rejection is also very high in individuals lacking IFN-gammaR1 and infected with mycobacteria. Moreover, high levels of circulating IFN-gamma account for this high rate of rejection. Ifngr1-/- mice reject even syngeneic grafts from IFN-gammaR1-expressing mice, in all conditions resulting in high serum IFN-gamma levels, including mycobacterial disease and intramuscular injections of rAAV-IFN-gamma. We have shown that IFN-gamma is necessary and sufficient for HSCT graft rejection. IFN-gamma has already been shown to have a direct inhibitory effect on myeloid, erythroid, megakaryocyte, and multipotent colony formation in human cultures in vitro [42,43]. Moreover, in long-term bone marrow cultures-the in vitro assay best mimicking the complex interactions occurring in intact bone marrow-Selleri et al. showed that local IFN-gamma overproduction by stromal cells inhibits haematopoiesis [44]. Two mechanisms seem to be responsible for the anti-haematopoietic effect of IFN-gamma: the direct killing of stem cells and the inhibition of cell cycling [44,45]. The exposure of primitive human haematopoietic stem cells to IFN-gamma in vitro increases Fas antigen expression, thereby rendering the cells more susceptible to apoptosis [46]. In vivo studies in mouse models have confirmed these results. Transgenic mice expressing multiple copies of the IFN-gamma gene, leading to high levels of IFN-gamma production in the bone marrow and thymus, display hypocellularity, and multiple alterations of the immune system [47]. There is also a strong correlation between the degree of heamatopoietic suppression and the level of IFN-gamma in vitro [48,49]. Altogether, these observations most likely account for the detrimental effects of high levels of circulating IFN-gamma in IFN-gammaR1-deficient mice and humans undergoing HSCT.
###end p 86
###begin p 87
###xml 310 322 298 310 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">M. fortuitum</named-content>
###xml 407 409 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b015">15</xref>
###xml 604 605 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b007">7</xref>
###xml 820 822 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b050">50</xref>
###xml 1150 1152 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b051">51</xref>
###xml 1153 1155 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b053">53</xref>
###xml 1487 1489 1427 1429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b054">54</xref>
###xml 1697 1699 1637 1639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b016">16</xref>
###xml 1700 1702 1640 1642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b055">55</xref>
###xml 1948 1950 1880 1882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050026-b056">56</xref>
###xml 136 142 <span type="species:ncbi:9606">people</span>
###xml 310 322 <span type="species:ncbi:1766">M. fortuitum</span>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
###xml 913 917 <span type="species:ncbi:10090">mice</span>
###xml 1088 1093 <span type="species:ncbi:9606">human</span>
###xml 1254 1262 <span type="species:ncbi:9606">patients</span>
###xml 1338 1344 <span type="species:ncbi:9606">people</span>
###xml 1806 1811 <span type="species:ncbi:10090">mouse</span>
###xml 1849 1857 <span type="species:ncbi:9606">patients</span>
###xml 1965 1973 <span type="species:ncbi:9606">patients</span>
###xml 2072 2076 <span type="species:ncbi:10090">mice</span>
The negative impact of high IFN-gamma levels, leading to HSCT graft rejection, has important clinical implications for the treatment of people with complete IFN-gammaR1 deficiency. Attempts could be made to decrease levels of circulating IFN-gamma before HSCT. As recently shown, antibiotics may not eradicate M. fortuitum infection, but they do markedly decrease serum IFN-gamma concentration before HSCT [15]. Prolonged treatment with multiple anti-mycobacterial antibiotics is therefore required, but is unlikely to decrease IFN-gamma levels sufficiently and is unlikely to cure most of the patients [7]. In this study, we explored the use of specific antibodies to deplete the blood of IFN-gamma. As anti-IFN-gamma antibodies alone were not sufficient for IFN-gamma depletion, we also used anti-IL-12p40 antibodies [50] to achieve efficient depletion of IFN-gamma in the serum. Infected IFN-gammaR1-deficient mice treated in this way displayed engraftment and control of the mycobacterial infection after HSCT. Anti-IL-12 and anti-IFN-gamma antibodies have already been used to treat human immune diseases, such as psoriasis and Crohn's disease [51-53]. The clinical use of these antibodies before HSCT is therefore feasible in IFN-gammaR1-deficient patients. Our study paves the way for improvements in transplantation conditions in people with IFN-gammaR1 deficiency, or with other diseases associated with elevated levels of circulating IFN-gamma, such as IFN-gammaR2 deficiency [54]. We can also speculate that the use of such antibodies may also reduce the risks of HSCT rejection, improving engraftment, in other settings, such as HSCT from a haplo-identical or matched unrelated donor [16,55]. Although we did not observe any detrimental effect of rAAV-IFN-gamma an HLA-identical setting in our mouse model, the depletion of IFN-gamma in patients with conditions associated with high rates of graft rejection, such as HLA-II deficiency [56], or in other patients undergoing haplo-identical transplantations, might be beneficial. Further experimental studies in mice should be done before the corresponding clinical trials can be undertaken.
###end p 87
###begin p 88
###xml 150 158 <span type="species:ncbi:9606">patients</span>
###xml 310 315 <span type="species:ncbi:9606">Human</span>
We would like to thank Anne-Marie Douar from Genethon, Evry for rAAV production. We also thank Joachim Roesler for personal communications concerning patients and Alain Fischer for initially suggesting the potential role of IFN-gamma in graft rejection. We would like to thank all members of the Laboratory of Human Genetics of Infectious Diseases for helpful discussions.
###end p 88
###begin title 89
Abbreviations
###end title 89
###begin p 90
###xml 0 19 0 19 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Mycobacterium bovis</named-content>
###xml 0 19 <span type="species:ncbi:1765">Mycobacterium bovis</span>
###xml 20 44 <span type="species:ncbi:33892">bacillus Calmette-Guerin</span>
Mycobacterium bovis bacillus Calmette-Guerin
###end p 90
###begin p 91
double knock-out
###end p 91
###begin p 92
haematopoietic stem cell transplantation
###end p 92
###begin p 93
Interferon-gamma
###end p 93
###begin p 94
Interferon-gamma receptor 1
###end p 94
###begin p 95
recombinant adeno-associated viral vector encoding IFN-gamma
###end p 95
###begin title 96
References
###end title 96
###begin article-title 97
###xml 32 35 <span type="species:ncbi:9606">Man</span>
###xml 37 41 <span type="species:ncbi:9606">OMIM</span>
###xml 63 68 <span type="species:ncbi:9606">human</span>
Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders
###end article-title 97
###begin article-title 98
###xml 52 57 <span type="species:ncbi:9606">human</span>
Genetic dissection of immunity to mycobacteria: the human model
###end article-title 98
###begin article-title 99
Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features
###end article-title 99
###begin article-title 100
###xml 43 49 <span type="species:ncbi:9606">infant</span>
Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection
###end article-title 100
###begin article-title 101
A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection
###end article-title 101
###begin article-title 102
In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma
###end article-title 102
###begin article-title 103
Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies
###end article-title 103
###begin article-title 104
###xml 16 24 <span type="species:ncbi:9606">children</span>
Tuberculosis in children and adults: two distincts genetic diseases
###end article-title 104
###begin article-title 105
###xml 83 89 <span type="species:ncbi:9606">humans</span>
Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans
###end article-title 105
###begin article-title 106
###xml 0 22 <span type="species:ncbi:1639">Listeria monocytogenes</span>
###xml 67 72 <span type="species:ncbi:9606">child</span>
Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options
###end article-title 106
###begin article-title 107
###xml 102 105 <span type="species:ncbi:33892">BCG</span>
Correlation of granuloma structure with clinical outcome defines two types of idiopathic disseminated BCG infection
###end article-title 107
###begin article-title 108
Correction of complete interferon-gamma receptor 1 deficiency by bone marrow transplantation
###end article-title 108
###begin article-title 109
Hematopoietic stem cell transplantation for complete IFN-gamma receptor 1 deficiency: a multi-institutional survey
###end article-title 109
###begin article-title 110
###xml 11 30 <span type="species:ncbi:1764">Mycobacterium avium</span>
Persistent Mycobacterium avium infection following nonmyeloablative allogeneic peripheral blood stem cell transplantation for interferon-gamma receptor-1 deficiency
###end article-title 110
###begin article-title 111
###xml 56 61 <span type="species:ncbi:9606">child</span>
###xml 87 110 <span type="species:ncbi:1766">Mycobacterium fortuitum</span>
Successful hematopoietic stem cell transplantation in a child with active disseminated Mycobacterium fortuitum infection and interferon-gamma receptor 1 deficiency
###end article-title 111
###begin article-title 112
Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99
###end article-title 112
###begin article-title 113
###xml 19 23 <span type="species:ncbi:10090">mice</span>
Immune response in mice that lack the interferon-gamma receptor
###end article-title 113
###begin article-title 114
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Multiple defects of immune cell function in mice with disrupted interferon-gamma genes
###end article-title 114
###begin article-title 115
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 117 133 <span type="species:ncbi:5664">Leishmania major</span>
Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response
###end article-title 115
###begin article-title 116
###xml 63 84 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Impact of interferon-gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis
###end article-title 116
###begin article-title 117
###xml 81 85 <span type="species:ncbi:10090">mice</span>
###xml 109 131 <span type="species:ncbi:90371">Salmonella typhimurium</span>
Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent Salmonella typhimurium
###end article-title 117
###begin article-title 118
###xml 32 38 <span type="species:ncbi:10090">murine</span>
The role of interferon-gamma in murine pneumococcal pneumonia
###end article-title 118
###begin article-title 119
###xml 40 67 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
Role for gamma interferon in control of herpes simplex virus type 1 reactivation
###end article-title 119
###begin article-title 120
###xml 56 82 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection
###end article-title 120
###begin article-title 121
###xml 20 35 <span type="species:ncbi:10090">transgenic mice</span>
High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas
###end article-title 121
###begin article-title 122
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 88 107 <span type="species:ncbi:1764">Mycobacterium avium</span>
Defects in cell-mediated immunity affect chronic, but not innate, resistance of mice to Mycobacterium avium infection
###end article-title 122
###begin article-title 123
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 97 121 <span type="species:ncbi:33892">Bacillus Calmette-Guerin</span>
Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide
###end article-title 123
###begin article-title 124
###xml 38 41 <span type="species:ncbi:33892">BCG</span>
Maintenance and control of the French BCG strain 1173-P2 (primary and secondary seeding lots)
###end article-title 124
###begin article-title 125
Differential requirement for interferon-gamma to restrict the growth of or eliminate some recently identified species of nontuberculous mycobacteria in vivo
###end article-title 125
###begin article-title 126
###xml 29 51 <span type="species:ncbi:272636">adeno-associated virus</span>
Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation
###end article-title 126
###begin article-title 127
###xml 21 43 <span type="species:ncbi:272636">adeno-associated virus</span>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice
###end article-title 127
###begin article-title 128
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies
###end article-title 128
###begin article-title 129
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice
###end article-title 129
###begin article-title 130
Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment
###end article-title 130
###begin article-title 131
###xml 49 57 <span type="species:ncbi:9606">children</span>
High levels of interferon gamma in the plasma of children with complete interferon gamma receptor deficiency
###end article-title 131
###begin article-title 132
###xml 67 70 <span type="species:ncbi:33892">BCG</span>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Generation of nitric oxide and clearance of interferon-gamma after BCG infection are impaired in mice that lack the interferon-gamma receptor
###end article-title 132
###begin article-title 133
###xml 197 214 <span type="species:ncbi:5811">Toxoplasma gondii</span>
Effector cells of both nonhemopoietic and hemopoietic origin are required for interferon (IFN)-gamma- and tumor necrosis factor (TNF)-alpha-dependent host resistance to the intracellular pathogen, Toxoplasma gondii
###end article-title 133
###begin article-title 134
IFN-gamma action in the media of the great elastic arteries, a novel immunoprivileged site
###end article-title 134
###begin article-title 135
The interferon gamma receptor
###end article-title 135
###begin article-title 136
###xml 45 50 <span type="species:ncbi:9606">human</span>
Distribution of interferon-gamma receptor in human tissues
###end article-title 136
###begin article-title 137
The molecular cell biology of interferon-gamma and its receptor
###end article-title 137
###begin article-title 138
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma
###end article-title 138
###begin article-title 139
Studies of interferon as a regulator of hematopoietic cell proliferation
###end article-title 139
###begin article-title 140
###xml 77 82 <span type="species:ncbi:9606">human</span>
Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition
###end article-title 140
###begin article-title 141
Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of heamatopoiesis and induces programmed cell death
###end article-title 141
###begin article-title 142
###xml 32 37 <span type="species:ncbi:9606">human</span>
Fas antigen expression on CD34+ human marrow cells is induced by interferon-gamma and tumor necrosis factor-alpha and potentiates cytokine-mediated hematopoietic suppression in vitro
###end article-title 142
###begin article-title 143
Bone marrow and thymus expression of interferon-gamma results in severe B-cell lineage reduction, T-cell lineage alterations, and hematopoietic progenitor deficiencies
###end article-title 143
###begin article-title 144
Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro
###end article-title 144
###begin article-title 145
Involvement of nitric oxide in bone marrow-derived natural suppressor activity; its dependence on IFNg
###end article-title 145
###begin article-title 146
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/23 in psoriais
###end article-title 146
###begin article-title 147
###xml 84 89 <span type="species:ncbi:9606">human</span>
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12p40 antibody in subjects with plaque psoriasis
###end article-title 147
###begin article-title 148
Anti-interleukin-12 antibody for active Crohn's disease
###end article-title 148
###begin article-title 149
Anti-interferon-gamma antibodies in the treatment of autoimmune diseases
###end article-title 149
###begin article-title 150
Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations
###end article-title 150
###begin article-title 151
Allogenic hematopoietic transplantation and natural killer cell recognition of missing self
###end article-title 151
###begin article-title 152
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and pre-existing viral infections
###end article-title 152
###begin p 153
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. MR, CS, JLG, and JLC designed the study and contributed to the writing. MR and CS performed the experiments. MR, CS, GV, LR, JFE, HD, JLG, and JLC analyzed the data. LR provided the antibody and contributed to the design of the cytokine neutralisation experiment. JFE did the histology analysis.
###end p 153
###begin p 154
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
###xml 111 116 <span type="species:ncbi:9606">Human</span>
Funding: This work received financial support from the association Vaincre La Mucoviscidose. The Laboratory of Human Genetics of Infectious Diseases is supported in part by grants from the Schlumberger and BNP Paribas Foundations, the March of Dimes, and by EU grant QLK2-CT-2002-00846. Jean-Laurent Casanova is an International Scholar of the Howard Hughes Medical Institute. C. Soudais is supported by the Association Francaise contre les Myopathies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 154
###begin p 155
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 155

